Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristina Larsson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
European Journal of Human Genetics : EJHG|June 7, 2007
A comprehensive screen for SNP associations on chromosome region 5q31-33 in Swedish/Norwegian celiac disease familiesSilja Svanstrøm Amundsen, Svetlana Adamovic, Asa Hellqvist, et al.
Nature Reviews. Drug Discovery|December 15, 2019
Therapies for rare diseases: therapeutic modalities, progress and challenges aheadErik Tambuyzer, Benjamin Vandendriessche, Christopher P Austin, et al.
Nature Reviews. Drug Discovery|January 9, 2020
Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges aheadErik Tambuyzer, Benjamin Vandendriessche, Christopher P Austin, et al.
Neuropsychobiology|May 15, 2009
DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association studyErik G Jönsson, Peter Saetre, Maria Vares, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2024
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in EuropeGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2023
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Gene Therapy|March 14, 2024
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, et al.
Frontiers in Medicine|September 13, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveMaria E Sheean, Frauke Naumann-Winter, Giuseppe Capovilla, et al.
Drug Discovery Today|October 9, 2017
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditionsMaria E Sheean, Violeta Stoyanova-Beninska, Giuseppe Capovilla, et al.
Drug Discovery Today|April 29, 2020
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizationsRick A Vreman, Angela S de Ruijter, Anna Zawada, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
European Journal of Human Genetics : EJHG|June 7, 2007
A comprehensive screen for SNP associations on chromosome region 5q31-33 in Swedish/Norwegian celiac disease familiesSilja Svanstrøm Amundsen, Svetlana Adamovic, Asa Hellqvist, et al.
Nature Reviews. Drug Discovery|December 15, 2019
Therapies for rare diseases: therapeutic modalities, progress and challenges aheadErik Tambuyzer, Benjamin Vandendriessche, Christopher P Austin, et al.
Nature Reviews. Drug Discovery|January 9, 2020
Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges aheadErik Tambuyzer, Benjamin Vandendriessche, Christopher P Austin, et al.
Neuropsychobiology|May 15, 2009
DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an association studyErik G Jönsson, Peter Saetre, Maria Vares, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 3, 2024
Navigating the orphan medicinal product designation: Evidence requirements for gene therapies in EuropeGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 5, 2023
The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M Palomo, Tomas Pose-Boirazian, Frauke Naumann-Winter, et al.
Gene Therapy|March 14, 2024
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, et al.
Frontiers in Medicine|September 13, 2021
Defining Satisfactory Methods of Treatment in Rare Diseases When Evaluating Significant Benefit-The EU Regulator's PerspectiveMaria E Sheean, Frauke Naumann-Winter, Giuseppe Capovilla, et al.
Drug Discovery Today|October 9, 2017
Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditionsMaria E Sheean, Violeta Stoyanova-Beninska, Giuseppe Capovilla, et al.
Drug Discovery Today|April 29, 2020
Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizationsRick A Vreman, Angela S de Ruijter, Anna Zawada, et al.
Pageof 5